查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602195

旅行疫苗市场：按类型、疾病分类 - 全球预测 2025-2030

Travel Vaccines Market by Type (Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines), Disease (DPT, Hepatitis A, Hepatitis B) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年旅行疫苗市值为82.6亿美元，预计2024年将达到90.9亿美元，复合年增长率为10.06%，到2030年将达到161.8亿美元。

旅行疫苗，也称为旅行免疫接种，对于确保前往感染疾病流行地区的个人的健康安全至关重要。旅行疫苗的需求源于其在预防旅行者感染特定地区流行的疾病（如黄热病、甲型肝炎和伤寒）方面的作用。其应用主要针对国际旅行的个人，在个人旅行者、商务旅行者、军事人员和外籍人士等领域找到最终用途。

主要市场统计
基准年[2023] 82.6亿美元
预测年份 [2024] 90.9亿美元
预测年份 [2030] 161.8亿美元
复合年增长率（%） 10.06%

影响该市场成长的关键因素是全球化、旅游业和业务扩张导致国际旅行频率的增加。此外，人们对健康风险的认识不断提高以及卫生当局的严格监管也推动了市场的发展。疫苗开发方面的技术进步，例如联合疫苗的推出，正在提供更多的商机。为了获利，鼓励公司投资开发具有持久保护作用和副作用较少的疫苗。此外，传播旅行疫苗讯息的数位平台有可能扩大市场范围。

然而，市场开拓也面临挑战，包括开发新疫苗的成本高昂以及延迟市场进入的监管障碍。公众对疫苗接种的抵制和错误讯息也可能阻碍市场成长。此外，供应链中断（例如全球健康危机期间出现的供应链中断）也可能会阻碍供应。

需要创新的领域包括针对新出现疾病的疫苗的研究和开发、基于旅行者檔案的个人化疫苗接种计划以及增强的疫苗输送机制（例如微针贴片）。市场是动态的，受到地缘政治和环境变化的影响，需要市场相关人员保持警惕和适应，以应对新出现的健康威胁。为了有效克服这些挑战并抓住机会，市场相关人员必须专注于与卫生机构的合作，利用资料分析进行市场预测，并加强传播策略。

市场动态：揭示快速发展的旅游疫苗市场的关键市场洞察

供需的动态交互作用正在改变旅行疫苗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 国际观光日益普及
    • 感染疾病的蔓延与联合疫苗的开发
    • 低温运输仓储基础设施的最新投资和改进
  • 市场限制因素
    • 旅行者缺乏意识
  • 市场机会
    • 疫苗新技术的创新与进展
    • 政府/组织的免疫和疫苗开发资助和倡议
  • 市场挑战
    • 疫苗处理和储存问题

波特的五力战略工具驾驭旅游疫苗市场

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解旅行疫苗市场的外部影响

外部宏观环境因素在塑造旅行疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解旅行疫苗市场的竞争格局

对旅行疫苗市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵旅游疫苗市场供应商的绩效评估

FPNV 定位矩阵是评估旅游疫苗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 国际观光日益普及
      • 感染疾病的传播和联合疫苗的开发
      • 低温运输仓储基础设施的最新投资和改进
    • 抑制因素
      • 旅客认知度低
    • 机会
      • 新疫苗技术的创新与进步
      • 政府和组织为免疫和疫苗开发提供的资金和努力
    • 任务
      • 疫苗处理和储存问题
  • 市场区隔分析
    • 类型：引发免疫反应的 DNA 疫苗的进展
    • 疾病：根据旅行者对肝炎疫苗的需求优先考虑
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章 旅行疫苗市场：依类型

  • 减毒疫苗
  • 结合疫苗
  • DNA疫苗
  • 惰性疫苗
  • 重组载体疫苗
  • 次单位疫苗
  • 类毒素疫苗

第七章 旅行疫苗市场：依疾病分类

  • 二氧化硅
  • 甲型肝炎
  • B型肝炎
  • 日本脑炎
  • 麻疹和腮腺炎
  • 脑膜炎奈瑟菌
  • 狂犬病
  • 伤寒
  • 水痘
  • 黄热病

第八章美洲旅行疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太旅行疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲旅行疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 印度首个本土甲型肝炎疫苗在海德拉巴上市
    • FDA 已核准PENBRAYA，这是第一个也是唯一一个用于预防导致青少年病菌感染的五种最常见血清群的疫苗。
    • 辉瑞和 BioNTech 获得美国FDA核准2023-2024 年 COVID-19 疫苗

公司名单

  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited
  • Cadila Pharmaceuticals Limited
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Novartis AG
  • Dynavax Technologies Corporation
  • CSL Limited
  • Emergent BioSolutions Inc.
  • Bio-Med（P）Limited
  • Bharat Biotech Ltd.
  • Indian Immunologicals Ltd.
  • Dano Vaccines & Biologicals Private Limited
  • Bavarian Nordic A/S
  • Johnson & Johnson Services, Inc
  • Pfizer Inc.
  • Incepta Pharmaceuticals Ltd.
  • GlaxoSmithKline PLC
  • Serum Institute of India Pvt. Ltd.
  • Abbott Laboratories
  • AstraZeneca PLC
  • Walvax Biotechnology Co., Ltd.
  • Bio-Manguinhos
  • Valneva SE
  • Sanofi SA
  • Biological E Limited
Product Code: MRR-0316851957A3

The Travel Vaccines Market was valued at USD 8.26 billion in 2023, expected to reach USD 9.09 billion in 2024, and is projected to grow at a CAGR of 10.06%, to USD 16.18 billion by 2030.

Travel vaccines, also known as travel immunizations, are crucial for ensuring the health safety of individuals traveling to regions with prevalent infectious diseases. The necessity of travel vaccines stems from their role in preventing travelers from contracting diseases such as yellow fever, hepatitis A, and typhoid, which are prevalent in certain geographical areas. Their application is primarily focused on individuals who travel internationally, and they find end-use across segments such as individual tourists, business travelers, military personnel, and expatriates.

KEY MARKET STATISTICS
Base Year [2023] USD 8.26 billion
Estimated Year [2024] USD 9.09 billion
Forecast Year [2030] USD 16.18 billion
CAGR (%) 10.06%

A significant factor influencing the growth of this market is the increasing international travel frequency, driven by globalization, tourism, and business expansion. Additionally, heightened awareness of health risks and stringent regulations by health authorities also propel the market forward. Technological advancements in vaccine development, such as the introduction of combination vaccines, present further opportunities. For businesses to capitalize, investing in the development of vaccines with longer-lasting protection and fewer side effects is recommended. Moreover, digital platforms for disseminating travel vaccine information can expand market reach.

However, the market is faced with challenges, such as the high cost of developing new vaccines and regulatory hurdles that can delay market entry. Public resistance to vaccination and misinformation can also hinder market growth. Furthermore, supply chain disruptions, as observed during global health crises, can impede availability.

Areas ripe for innovation include the research and development of vaccines against emerging diseases, personalized vaccine schedules based on traveler profiles, and enhanced vaccine delivery mechanisms, such as micro-needle patches. The market is dynamic, influenced by geopolitical and environmental changes, which necessitate vigilance and adaptability from market players to address emerging health threats. To effectively navigate these challenges and seize opportunities, market players must focus on collaboration with health organizations, leverage data analytics for market forecasting, and maintain robust communication strategies to counter misinformation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Travel Vaccines Market

The Travel Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Popularity of International Tourism
    • Growing Prevalence of Infectious Diseases and Development of Combination Vaccines
    • Recent Investments and Improvement in Cold Chain Storage Infrastructure
  • Market Restraints
    • Limited Awareness Amongst Travelers
  • Market Opportunities
    • Innovations in Novel Vaccine Technologies and Advancements
    • Government and Organizational Funding and Initiatives for Immunization and Vaccine Development
  • Market Challenges
    • Issues Related to Vaccine Handling and Storage

Porter's Five Forces: A Strategic Tool for Navigating the Travel Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Travel Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Travel Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Travel Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Travel Vaccines Market

A detailed market share analysis in the Travel Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Travel Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Travel Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Travel Vaccines Market, highlighting leading vendors and their innovative profiles. These include Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Cadila Pharmaceuticals Limited, Shenzhen Kangtai Biological Products Co., Ltd., Novartis AG, Dynavax Technologies Corporation, CSL Limited, Emergent BioSolutions Inc., Bio-Med (P) Limited, Bharat Biotech Ltd., Indian Immunologicals Ltd., Dano Vaccines & Biologicals Private Limited, Bavarian Nordic A/S, Johnson & Johnson Services, Inc, Pfizer Inc., Incepta Pharmaceuticals Ltd., GlaxoSmithKline PLC, Serum Institute of India Pvt. Ltd., Abbott Laboratories, AstraZeneca PLC, Walvax Biotechnology Co., Ltd., Bio-Manguinhos, Valneva SE, Sanofi S.A., and Biological E Limited.

Market Segmentation & Coverage

This research report categorizes the Travel Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines, Inactive Vaccines, Recombinant Vector Vaccines, Subunit Vaccines, and Toxoid Vaccines.
  • Based on Disease, market is studied across DPT, Hepatitis A, Hepatitis B, Japanese Encephalitis, Measles and Mumps, Meningococcal, Rabies, Typhoid, Varicella, and Yellow Fever.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Popularity of International Tourism
      • 5.1.1.2. Growing Prevalence of Infectious Diseases and Development of Combination Vaccines
      • 5.1.1.3. Recent Investments and Improvement in Cold Chain Storage Infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. Limited Awareness Amongst Travelers
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in Novel Vaccine Technologies and Advancements
      • 5.1.3.2. Government and Organizational Funding and Initiatives for Immunization and Vaccine Development
    • 5.1.4. Challenges
      • 5.1.4.1. Issues Related to Vaccine Handling and Storage
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Advancements in DNA vaccines to induce immune response
    • 5.2.2. Disease: Need based preference for hepatitis vaccines among travelers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Travel Vaccines Market, by Type

  • 6.1. Introduction
  • 6.2. Attenuated Vaccines
  • 6.3. Conjugate Vaccines
  • 6.4. DNA Vaccines
  • 6.5. Inactive Vaccines
  • 6.6. Recombinant Vector Vaccines
  • 6.7. Subunit Vaccines
  • 6.8. Toxoid Vaccines

7. Travel Vaccines Market, by Disease

  • 7.1. Introduction
  • 7.2. DPT
  • 7.3. Hepatitis A
  • 7.4. Hepatitis B
  • 7.5. Japanese Encephalitis
  • 7.6. Measles and Mumps
  • 7.7. Meningococcal
  • 7.8. Rabies
  • 7.9. Typhoid
  • 7.10. Varicella
  • 7.11. Yellow Fever

8. Americas Travel Vaccines Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Travel Vaccines Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Travel Vaccines Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. India's First Indigenously Developed Hepatitis A Vaccine Launched In Hyderabad
    • 11.3.2. FDA Approves PENBRAYA, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
    • 11.3.3. Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Companies Mentioned

  • 1. Merck & Co., Inc.
  • 2. Takeda Pharmaceutical Company Limited
  • 3. Cadila Pharmaceuticals Limited
  • 4. Shenzhen Kangtai Biological Products Co., Ltd.
  • 5. Novartis AG
  • 6. Dynavax Technologies Corporation
  • 7. CSL Limited
  • 8. Emergent BioSolutions Inc.
  • 9. Bio-Med (P) Limited
  • 10. Bharat Biotech Ltd.
  • 11. Indian Immunologicals Ltd.
  • 12. Dano Vaccines & Biologicals Private Limited
  • 13. Bavarian Nordic A/S
  • 14. Johnson & Johnson Services, Inc
  • 15. Pfizer Inc.
  • 16. Incepta Pharmaceuticals Ltd.
  • 17. GlaxoSmithKline PLC
  • 18. Serum Institute of India Pvt. Ltd.
  • 19. Abbott Laboratories
  • 20. AstraZeneca PLC
  • 21. Walvax Biotechnology Co., Ltd.
  • 22. Bio-Manguinhos
  • 23. Valneva SE
  • 24. Sanofi S.A.
  • 25. Biological E Limited

LIST OF FIGURES

  • FIGURE 1. TRAVEL VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. TRAVEL VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TRAVEL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TRAVEL VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INACTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RECOMBINANT VECTOR VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TRAVEL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DPT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY JAPANESE ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MEASLES AND MUMPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 51. JAPAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. MALAYSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MALAYSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 55. PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 57. SINGAPORE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. SINGAPORE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 61. TAIWAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. TAIWAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. THAILAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. THAILAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 65. VIETNAM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. VIETNAM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. DENMARK TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. DENMARK TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 72. EGYPT TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. EGYPT TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. FINLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. FINLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. FRANCE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. FRANCE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. GERMANY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. GERMANY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 80. ISRAEL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. ISRAEL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. ITALY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. ITALY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 86. NIGERIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. NIGERIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 88. NORWAY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. NORWAY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. POLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. POLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. QATAR TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. QATAR TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. RUSSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. RUSSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 100. SPAIN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SPAIN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. SWEDEN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SWEDEN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 106. TURKEY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. TURKEY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 112. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 113. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023